93 Ces Urol 2023; 27(2): 86-94 PŘEHLEDOVÉ ČLÁNKY 7. Hussain M, Tangen CM, Higano C, et al. Absolute Prostate‑Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006; 24(24): 3984–90. 8. Lozar T, Gersak K, Cemazar M, Kuhar CG, Jesenko T. The biology and clinical potential of circulating tumor cells. Radiol Oncol. 2019; 53(2): 131–47. 9. Dathathri E, Isebia KT, Abali F, et al. Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer. Front Oncol. 2022; 12: 863472. 10. de Bono JS, Scher HI, Montgomery RB, et al. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration‑Resistant Prostate Cancer. Clin Cancer Res. 2008; 14(19): 6302–9. 11. Scher HI, Heller G, Molina A, et al. Circulating Tumor Cell Biomarker Panel as an Individual‑Level Su‑ rrogate for Survival in Metastatic Castration‑Resistant Prostate Cancer. J Clin Oncol. 2015; 33(12): 348–55. 12. Vasseur A, Kiavue N, Bidard F, Pierga J, Cabel L. Clinical utility of circulating tumor cells: an update. Mol Oncol. 2021; 15(6): 1647–66. 13. Čapoun O, Soukup V, Mikulová V, et al. Cirkulující nádorové buňky a prognóza karcinomu prostaty. Čas. Lék. čes. 2014; 152: 72–77. 14. Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: A sys‑ tematic review and meta‑analysis of 76 studies. Acta Oncol. 2015; 54(7): 961–70. 15. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association with Survival and Activated Vascular Endothelial Growth Factor Pathway A Report of the Tumour Angiogenesis Research Group. J Clin Oncol. 2006; 24(26): 4301–8. 16. Li F, Xiang H, Pang Z, et al. Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta‑analysis. Cancer Med.2020; 9(19): 7341–51. 17. Epstein JI, Egevad L, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2016; 40(2): 244–52. 18. Karnofsky DA, Burchenal JH. Present status of clinical cancer chemotherapy. Am J Med. 1950; 8(6): 767–88. 19. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6): 649–55. 20. Kapoor R, Saxena AK, Vasudev P, Sundriyal D, Kumar A. Cancer induced bone pain: current man‑ agement and future perspectives. Med Oncol. 2021; 38(11): 134. 21. Zajączkowska R, Kocot‑Kępska M, Leppert W, Wordliczek J. Bone Pain in Cancer Patients: Mechanisms and Current Treatment. Int J Mol Sci. 2019; 20(23): 6047. 22. Yoong J, Poon P. Principles of cancer pain management: An overview and focus on pharmacological and interventional strategies. Aust J Gen Pract. 2018; 47(11): 758–62. 23. Batson OV. The function of the vertebral veins and their role in the spread of metastases: Ann Surg. 1940; 112(1): 138–49. 24. Smith AE, Muralidharan A, Smith MT. Prostate cancer induced bone pain: pathobiology, current treatments and pain responses from recent clinical trials. Discov Oncol. 2022; 13(1): 108. 25. Yoneda T, Hiasa M, Nagata Y, Okui T, White FA. Acidic microenvironment and bone pain in cancer ‑colonized bone. Bonekey Rep. 2015; 4: 690. 26. Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain Predicts Overall Survival in Men with Metastatic Castration‑Refractory Prostate Cancer. J Clin Oncol. 2008; 26(15): 2544–9. 27. Jenšovský J. Sarkopenie: definice a diagnostika nové nemoci. Clin Osteol. 2019; 24(1): 14–18. 28. Cruz‑Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagno‑ sis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4): 412–23.
RkJQdWJsaXNoZXIy NDA4Mjc=